MA49043B1 - Formulation stable d'anticorps - Google Patents

Formulation stable d'anticorps

Info

Publication number
MA49043B1
MA49043B1 MA49043A MA49043A MA49043B1 MA 49043 B1 MA49043 B1 MA 49043B1 MA 49043 A MA49043 A MA 49043A MA 49043 A MA49043 A MA 49043A MA 49043 B1 MA49043 B1 MA 49043B1
Authority
MA
Morocco
Prior art keywords
antibodies
muc16
bind
antibody formulation
stable antibody
Prior art date
Application number
MA49043A
Other languages
English (en)
Other versions
MA49043A (fr
Inventor
Qingyan Hu
Dingjiang Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA49043A publication Critical patent/MA49043A/fr
Publication of MA49043B1 publication Critical patent/MA49043B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps bispécifiques (bsabs) : anticorps anti-muc16 qui se lient à la fois à muc16 et à cd3 et activent les cellules t par l'intermédiaire du complexe cd3 en présence de tumeurs exprimant muc16. L'invention concerne également des anticorps igg humains qui se lient à des anticorps anti-muc16 humains (anticorps monospécifiques), des conjugués anticorps-médicament anti-muc16 qui inhibent la croissance tumorale in vivo, les anticorps sont utiles pour le traitement de divers cancers, y compris le cancer de l'ovaire.
MA49043A 2017-04-06 2018-03-23 Formulation stable d'anticorps MA49043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482270P 2017-04-06 2017-04-06
PCT/US2018/024032 WO2018187057A1 (fr) 2017-04-06 2018-03-23 Formulation stable d'anticorps

Publications (2)

Publication Number Publication Date
MA49043A MA49043A (fr) 2020-02-12
MA49043B1 true MA49043B1 (fr) 2023-11-30

Family

ID=62028099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49043A MA49043B1 (fr) 2017-04-06 2018-03-23 Formulation stable d'anticorps

Country Status (29)

Country Link
US (2) US11603407B2 (fr)
EP (2) EP4249512A3 (fr)
JP (1) JP7229171B2 (fr)
KR (1) KR102667484B1 (fr)
CN (1) CN110709062B (fr)
AR (1) AR111455A1 (fr)
AU (1) AU2018247501A1 (fr)
BR (1) BR112019020246A2 (fr)
CA (1) CA3059087A1 (fr)
CL (1) CL2019002828A1 (fr)
CO (1) CO2019011021A2 (fr)
DK (1) DK3606504T3 (fr)
EA (1) EA201992377A1 (fr)
ES (1) ES2955062T3 (fr)
FI (1) FI3606504T3 (fr)
HR (1) HRP20231282T1 (fr)
HU (1) HUE063509T2 (fr)
IL (1) IL269499A (fr)
LT (1) LT3606504T (fr)
MA (1) MA49043B1 (fr)
MX (1) MX2019011207A (fr)
PH (1) PH12019502123A1 (fr)
PL (1) PL3606504T3 (fr)
PT (1) PT3606504T (fr)
RS (1) RS64680B1 (fr)
SG (2) SG11201908540PA (fr)
SI (1) SI3606504T1 (fr)
TW (1) TWI795396B (fr)
WO (1) WO2018187057A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JP7324710B2 (ja) 2017-02-21 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 肺癌の処置のための抗ｐｄ－１抗体
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
US20210380694A1 (en) 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
LT3880186T (lt) 2018-11-14 2024-06-10 Regeneron Pharmaceuticals, Inc. Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti
CA3129901A1 (fr) 2019-02-18 2020-08-27 Eli Lilly And Company Formulation d'anticorps therapeutique
WO2020176699A1 (fr) 2019-02-28 2020-09-03 Regeneron Pharmaceuticals, Inc. Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
JP2022523804A (ja) 2019-03-06 2022-04-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN114786719A (zh) * 2019-10-02 2022-07-22 阿拉玛布治疗学股份有限公司 抗-连接蛋白抗体制剂
KR20220097928A (ko) * 2019-11-04 2022-07-08 이노비오 파마수티컬즈, 인크. 뇌암을 치료하기 위한 조합 요법
WO2021096278A1 (fr) * 2019-11-15 2021-05-20 삼성바이오에피스 주식회사 Composition en phase liquide pour médicament à base d'anticorps
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
KR102604984B1 (ko) * 2020-03-18 2023-11-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
JP7240512B2 (ja) 2020-05-26 2023-03-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
WO2021254447A1 (fr) * 2020-06-19 2021-12-23 神州细胞工程有限公司 Formulation stable pour anticorps monoclonal anti-pd-1 recombinant
CA3189666A1 (fr) * 2020-08-18 2022-02-24 William Jason Cummings Anticorps monoclonaux, compositions et procedes de detection du facteur d du complement
CN116134155A (zh) 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
AU2021337650A1 (en) 2020-09-03 2023-05-04 Regeneron Pharmaceuticals, Inc. Methods of treating cancer pain by administering a pd-1 inhibitor
JP2023545926A (ja) 2020-09-24 2023-11-01 メルク・シャープ・アンド・ドーム・エルエルシー プログラム死受容体１（ｐｄ－１）抗体とヒアルロニダーゼ変異体とそれらのフラグメントとの安定製剤およびその使用方法
MX2023009279A (es) 2021-02-11 2023-10-02 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
JP2024507866A (ja) 2021-02-23 2024-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することにより肺がんを処置する方法
CA3170902A1 (fr) 2021-03-23 2022-09-23 Jigar Desai Procedes de traitement du cancer chez des patients immunosupprimes ou immunocompromis par l'administration d'un inhibiteur pd-1
CA3220545A1 (fr) 2021-06-23 2022-12-29 Rainer Sigl Formulations d'anticorps anti-pd1
TW202345902A (zh) * 2022-04-14 2023-12-01 瑞士商百濟神州瑞士有限責任公司 含有ｐｄ－１抗體的穩定高濃度精胺酸配製物及其使用方法
TW202342098A (zh) * 2022-04-14 2023-11-01 瑞士商百濟神州瑞士有限責任公司 含有ｐｄ－１抗體的穩定高濃度氯化鈉配製物及其使用方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
BR0013542A (pt) 1999-08-23 2002-05-14 Dana Farber Cancer Inst Inc Moléculas b7-4 e usos para as mesmas
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
CA3016482A1 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
AU2001273096B8 (en) 2000-06-28 2005-10-13 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2002086083A2 (fr) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Procedes d'amelioration de la capacite de reaction de cellules t
WO2003042402A2 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
JP2004104681A (ja) 2002-09-12 2004-04-02 Renesas Technology Corp 入力バッファ回路
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
EP2357201B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP1896582A4 (fr) 2005-05-09 2009-04-08 Ono Pharmaceutical Co Anticorps monoclonaux humains pour mort programmée 1 (mp-1) et procédés pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associés à d'autres immunothérapies
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
BRPI0712224B8 (pt) 2006-06-02 2021-05-25 Regeneron Pharma anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
WO2009014708A2 (fr) 2007-07-23 2009-01-29 Cell Genesys, Inc. Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
WO2010029435A1 (fr) 2008-09-12 2010-03-18 Isis Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
EP2342228B1 (fr) 2008-09-12 2017-09-06 Oxford University Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
CA2998281C (fr) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Anticorps anti-pd-1 humains et leurs utilisations
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EP2393835B1 (fr) 2009-02-09 2017-04-05 Université d'Aix-Marseille Anticorps contre pd-1 et anticorps contre pd-l1 et leurs utilisations
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
AU2010303149B2 (en) 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
KR102432611B1 (ko) 2010-02-08 2022-08-16 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
EP2910572B1 (fr) 2010-11-11 2017-09-06 Versitech Limited Variants solubles pd-1, structures de fusion et utilisations de ceux-ci
PL2691112T3 (pl) 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
EP3058952A1 (fr) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations ayant une viscosité réduite
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
WO2013014668A1 (fr) 2011-07-24 2013-01-31 Curetech Ltd. Variants d'anticorps monoclonaux immunomodulateurs humanisés
MY170117A (en) 2011-08-01 2019-07-05 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN108771655A (zh) * 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
EP2807194A4 (fr) 2012-01-27 2015-12-02 Gliknik Inc Protéines de fusion comprenant des domaines charnières igg2
WO2013166500A1 (fr) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Anticorps anti-ccr4 monoclonaux humanisés maturés par affinité et leurs procédés d'utilisation
WO2013169693A1 (fr) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1
US20130303250A1 (en) 2012-05-11 2013-11-14 Ryan Moore Method of Playing a Card Game
BR122022015975B1 (pt) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
JP6312659B2 (ja) 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
SG10201702421TA (en) 2012-10-02 2017-05-30 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
EP2911669B1 (fr) 2012-10-26 2024-04-10 The University of Chicago Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
CA2905798C (fr) 2013-03-15 2023-01-24 Genentech, Inc. Biomarqueurs et methodes de traitement d'etats associes a pd-1 et pd-l1
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
WO2014179664A2 (fr) 2013-05-02 2014-11-06 Anaptysbio, Inc. Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
WO2014194293A1 (fr) 2013-05-30 2014-12-04 Amplimmune, Inc. Méthodes améliorées de sélection de patients pouvant être soumis à des thérapies ciblant pd-1 ou b7-h4, et polythérapies associées
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
US9873740B2 (en) 2013-07-16 2018-01-23 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
MX2016002273A (es) 2013-08-20 2016-05-31 Merck Sharp & Dohme Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
HUE062317T2 (hu) 2013-09-20 2023-10-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez
EP3049442A4 (fr) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
KR102331663B1 (ko) 2013-09-27 2021-11-25 제넨테크, 인크. 항-pdl1 항체 제제
AU2014354384B2 (en) * 2013-11-29 2018-11-08 Ares Trading S.A. A liquid formulation of a fusion protein comprising TNFR and Fc region
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
MX2017004810A (es) 2014-10-14 2017-10-16 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
WO2016168716A1 (fr) 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprenant une combinaison d'un anticorps anti-pd-1 et d'un autre anticorps
CA3009161A1 (fr) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combinaison d'anticorps anti-pd-1 et d'anticorps bispecifiques anti-cd20/anti-cd3 pour traiter le cancer

Also Published As

Publication number Publication date
TW201900210A (zh) 2019-01-01
PL3606504T3 (pl) 2024-01-08
JP7229171B2 (ja) 2023-02-27
US20190040137A1 (en) 2019-02-07
EP4249512A2 (fr) 2023-09-27
HUE063509T2 (hu) 2024-01-28
LT3606504T (lt) 2023-09-11
WO2018187057A1 (fr) 2018-10-11
KR20190134743A (ko) 2019-12-04
CN110709062B (zh) 2024-03-08
SG10202111008QA (en) 2021-11-29
KR102667484B1 (ko) 2024-05-22
DK3606504T3 (en) 2023-09-04
CN110709062A (zh) 2020-01-17
CL2019002828A1 (es) 2019-12-27
EP4249512A3 (fr) 2023-11-22
FI3606504T3 (fi) 2023-08-23
BR112019020246A2 (pt) 2020-05-12
CA3059087A1 (fr) 2018-10-11
AR111455A1 (es) 2019-07-17
ES2955062T3 (es) 2023-11-28
MX2019011207A (es) 2019-12-11
AU2018247501A1 (en) 2019-10-31
CO2019011021A2 (es) 2020-01-17
US11603407B2 (en) 2023-03-14
JP2020516608A (ja) 2020-06-11
TWI795396B (zh) 2023-03-11
US20230183348A1 (en) 2023-06-15
PH12019502123A1 (en) 2020-06-29
IL269499A (en) 2019-11-28
EP3606504B1 (fr) 2023-07-19
EA201992377A1 (ru) 2020-02-17
PT3606504T (pt) 2023-09-04
SI3606504T1 (sl) 2023-10-30
SG11201908540PA (en) 2019-10-30
MA49043A (fr) 2020-02-12
EP3606504A1 (fr) 2020-02-12
HRP20231282T1 (hr) 2024-02-02
RS64680B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
MA49043B1 (fr) Formulation stable d'anticorps
PH12019500550A1 (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CO2018010919A2 (es) Moleculas de unión b7-h3 novedosas, conjugados anticuerpo - fármaco de los mismos y métodos de uso de los mismos
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
NZ604003A (en) Monoclonal antibodies against her2
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
MX2021011750A (es) Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
MX2020011487A (es) Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
WO2021067776A3 (fr) Anticorps anti-pd-l1 et conjugués anticorps-médicament
EA202092136A1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
MX2020011823A (es) Metodos para tratar cancer con combinacion de anticuerpo anti-muerte programada-1 (pd-1) y conjugado de anticuerpo anti-factor de tejido y farmaco.
MA46277B1 (fr) Anticorps anti-muc16-cd3 bi specifiques et conjugues d'anticorps anti-muc16 avec des anticancereux
EA202090689A1 (ru) Композиции и способы истощения клеток cd117+
MX2023010333A (es) Tratamiento conjunto de inmunoconjugados de variante il-2 que actuan sobre pd-1-y moleculas de union a fap/4-1bb.
MX2022005222A (es) Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.